DALLAS, October 15, 2018 /PRNewswire/ — Eclipse MedCorp, a leading medical device company, has expanded its portfolio by acquiring worldwide control of a novel, autologous point-of-care technology in regenerative medicine. In the transaction, Eclipse obtains exclusive rights to the intellectual property (IP) and will jointly own additional IP as it is developed.
“This acquisition marks a tremendous moment for Eclipse as we seek best-in-class solutions to serve our physicians and their patients,” said Tom O’Brien, CEO and Founder of Eclipse. “This significant technology will be rapidly commercialized in multiple fields of use on a worldwide basis. The acquisition will strengthen Eclipse’s position as a global leader in regenerative medicine for years to come.”
Dr. Sanjay Batra, President of Regenerative Medicine for Eclipse led the acquisition and introduced the technology to its Medical & Scientific Board at its annual meeting in Chicago on October 6, 2018.
The Eclipse Medical Advisory board is comprised of eminent dermatologists (Dr. Wilma Bergfeld, Dr. Neil Sadick and Dr. Jeffrey Rapaport) and plastic surgeons (Dr. Gordon Sasaki and Dr. Steven Dayan). Positive feedback was received by all members and Dr. Dayan noted that “this strategic move marks a major inflection point for Eclipse as it moves from being a distributor to an innovator, owner and manufacturer of world class medical technology.”
For more than 25 years, Eclipse has been an innovative leader in advancing medical technologies to bring medical and aesthetic supplies to practices in the United States and around the globe. Based in Dallas, TX Eclipse manufactures and distributes high-efficacy, affordable products to physicians that exceed patient expectations and put immediate profit into customers’ practices. To learn more about our industry-leading products and how to Eclipse the competition, visit www.EclipseMedGlobal.com.